# NRX Pharmaceuticals, Inc. (NRXP) · Edgar & Edgarette company card

> NRX Pharmaceuticals (NRXP) reported revenue of $1 million in FY2025, operating margin -1123% against a -3.8% median for pharmaceutical preparations, equity -123% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1719406 · fiscal year ended 2025-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/NRXP) · [JSON](https://www.pops4.com/boards/company/NRXP.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1M |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -1122.8% (prior year -Infinity%) |
| Net margin | -1980.8% |
| Operating cash flow | −$14M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $8M |
| Long-term debt | — |
| Total assets | $13M |
| Total equity | −$16M |
| Equity ÷ assets | -123.0% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -96.18 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed auditor change in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -1122.8% in FY2025

## Edgarette's reading

Exposure: revenue $1.4M (FY2025). Experience: one year on record; operating margin -1122.8%, up from null. Soundness: equity -123.0% of assets (liabilities exceed assets). Credibility: 3 audited years, moderate weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -1122.8% against a -3.8% median.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-01-16 ([filing](https://www.sec.gov/Archives/edgar/data/1719406/000143774926001455/0001437749-26-001455-index.htm))
- Item 4.01 Auditor change: 1, latest 2025-11-26 ([filing](https://www.sec.gov/Archives/edgar/data/1719406/000143774925036452/0001437749-25-036452-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-03-24 ([filing](https://www.sec.gov/Archives/edgar/data/1719406/000143774926009611/0001437749-26-009611-index.htm))

## Recent filings

- 8-K · filed 2026-11-02 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1719406/000143774926034284/0001437749-26-034284-index.htm)
- 8-K · filed 2026-10-16 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1719406/000143774926032828/0001437749-26-032828-index.htm)
- 8-K · filed 2026-10-05 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1719406/000143774926032042/0001437749-26-032042-index.htm)
- 8-K · filed 2026-09-16 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1719406/000143774926030492/0001437749-26-030492-index.htm)
- 8-K · filed 2026-09-14 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1719406/000143774926030228/0001437749-26-030228-index.htm)
- 8-K · filed 2026-08-17 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1719406/000143774926028111/0001437749-26-028111-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001719406.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1719406

## Cite

POPS4, Edgar & Edgarette: NRX Pharmaceuticals, Inc. (NRXP) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/NRXP. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.